Indiana university experience in the management of vaginal cancer

Bedatri Sinha, Frederick Stehman, Jeanne Schilder, Lori Clark, Higinia Cardenes

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose: To review our institutional experience in the treatment of primary vaginal cancer and identify predictors for outcome, in particular, recurrence rate. Materials and Methods: We retrospectively reviewed the charts of 45 patients identified as having primary squamous cell cancer and adenocarcinoma of the vagina and recorded information regarding both patient and tumor characteristics and treatment modalities. Treatment modalities included surgery and radiation with or without chemotherapy (6 patients), radiation alone (30 patients), and chemoradiation (9 patients). Then, univariate and multivariate analyses were used to identify factors, which predicted for recurrence. Kaplan-Meier survival curves were also generated. Results: The median follow-up time for all surviving patients was 5.8 years (range, 9-146 months). The mean and the median minimum tumor doses were 7300 cGy. The 5-year overall survival rate was 71%, and the 5-year progression-free survival rate was 77%. The 5-year overall survival rates by stage were carcinoma in situ with microinvasion and stage I, 92%; stage II, 82%; and stages III and IVA, 20% (P = 0.0005). The 5-year progression-free survival rates by stage were carcinoma in situ and stage I, 92%; stage II, 88%; and stages III and IVA, 30% (P = 0.00049). Of the factors analyzed, only stage predicted for a statistically significant increased risk for recurrence (P = 2.23E-0.05). Conclusions: Early-stage vaginal cancer can be successfully managed with radiation therapy with excellent rates of local control and survival. Patients with stages III and IV disease have a very poor outcome, and more aggressive therapies need to be investigated. Given the limited number of patients treated with chemotherapy and radiation, no definitive conclusions can be made regarding the impact of combined therapy in the management of this disease.

Original languageEnglish
Pages (from-to)686-693
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume19
Issue number4
DOIs
StatePublished - May 2009

Fingerprint

Vaginal Neoplasms
Survival Rate
Carcinoma in Situ
Radiation
Recurrence
Disease-Free Survival
Therapeutics
Drug Therapy
Squamous Cell Neoplasms
Kaplan-Meier Estimate
Disease Management
Neoplasms
Adenocarcinoma
Radiotherapy
Multivariate Analysis

Keywords

  • Brachytherapy
  • Chemotherapy
  • Radiotherapy
  • Vaginal cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Indiana university experience in the management of vaginal cancer. / Sinha, Bedatri; Stehman, Frederick; Schilder, Jeanne; Clark, Lori; Cardenes, Higinia.

In: International Journal of Gynecological Cancer, Vol. 19, No. 4, 05.2009, p. 686-693.

Research output: Contribution to journalArticle

@article{9167b98bd7d94620974173f50c68a635,
title = "Indiana university experience in the management of vaginal cancer",
abstract = "Purpose: To review our institutional experience in the treatment of primary vaginal cancer and identify predictors for outcome, in particular, recurrence rate. Materials and Methods: We retrospectively reviewed the charts of 45 patients identified as having primary squamous cell cancer and adenocarcinoma of the vagina and recorded information regarding both patient and tumor characteristics and treatment modalities. Treatment modalities included surgery and radiation with or without chemotherapy (6 patients), radiation alone (30 patients), and chemoradiation (9 patients). Then, univariate and multivariate analyses were used to identify factors, which predicted for recurrence. Kaplan-Meier survival curves were also generated. Results: The median follow-up time for all surviving patients was 5.8 years (range, 9-146 months). The mean and the median minimum tumor doses were 7300 cGy. The 5-year overall survival rate was 71{\%}, and the 5-year progression-free survival rate was 77{\%}. The 5-year overall survival rates by stage were carcinoma in situ with microinvasion and stage I, 92{\%}; stage II, 82{\%}; and stages III and IVA, 20{\%} (P = 0.0005). The 5-year progression-free survival rates by stage were carcinoma in situ and stage I, 92{\%}; stage II, 88{\%}; and stages III and IVA, 30{\%} (P = 0.00049). Of the factors analyzed, only stage predicted for a statistically significant increased risk for recurrence (P = 2.23E-0.05). Conclusions: Early-stage vaginal cancer can be successfully managed with radiation therapy with excellent rates of local control and survival. Patients with stages III and IV disease have a very poor outcome, and more aggressive therapies need to be investigated. Given the limited number of patients treated with chemotherapy and radiation, no definitive conclusions can be made regarding the impact of combined therapy in the management of this disease.",
keywords = "Brachytherapy, Chemotherapy, Radiotherapy, Vaginal cancer",
author = "Bedatri Sinha and Frederick Stehman and Jeanne Schilder and Lori Clark and Higinia Cardenes",
year = "2009",
month = "5",
doi = "10.1111/IGC.0b013e3181a12e1d",
language = "English",
volume = "19",
pages = "686--693",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Indiana university experience in the management of vaginal cancer

AU - Sinha, Bedatri

AU - Stehman, Frederick

AU - Schilder, Jeanne

AU - Clark, Lori

AU - Cardenes, Higinia

PY - 2009/5

Y1 - 2009/5

N2 - Purpose: To review our institutional experience in the treatment of primary vaginal cancer and identify predictors for outcome, in particular, recurrence rate. Materials and Methods: We retrospectively reviewed the charts of 45 patients identified as having primary squamous cell cancer and adenocarcinoma of the vagina and recorded information regarding both patient and tumor characteristics and treatment modalities. Treatment modalities included surgery and radiation with or without chemotherapy (6 patients), radiation alone (30 patients), and chemoradiation (9 patients). Then, univariate and multivariate analyses were used to identify factors, which predicted for recurrence. Kaplan-Meier survival curves were also generated. Results: The median follow-up time for all surviving patients was 5.8 years (range, 9-146 months). The mean and the median minimum tumor doses were 7300 cGy. The 5-year overall survival rate was 71%, and the 5-year progression-free survival rate was 77%. The 5-year overall survival rates by stage were carcinoma in situ with microinvasion and stage I, 92%; stage II, 82%; and stages III and IVA, 20% (P = 0.0005). The 5-year progression-free survival rates by stage were carcinoma in situ and stage I, 92%; stage II, 88%; and stages III and IVA, 30% (P = 0.00049). Of the factors analyzed, only stage predicted for a statistically significant increased risk for recurrence (P = 2.23E-0.05). Conclusions: Early-stage vaginal cancer can be successfully managed with radiation therapy with excellent rates of local control and survival. Patients with stages III and IV disease have a very poor outcome, and more aggressive therapies need to be investigated. Given the limited number of patients treated with chemotherapy and radiation, no definitive conclusions can be made regarding the impact of combined therapy in the management of this disease.

AB - Purpose: To review our institutional experience in the treatment of primary vaginal cancer and identify predictors for outcome, in particular, recurrence rate. Materials and Methods: We retrospectively reviewed the charts of 45 patients identified as having primary squamous cell cancer and adenocarcinoma of the vagina and recorded information regarding both patient and tumor characteristics and treatment modalities. Treatment modalities included surgery and radiation with or without chemotherapy (6 patients), radiation alone (30 patients), and chemoradiation (9 patients). Then, univariate and multivariate analyses were used to identify factors, which predicted for recurrence. Kaplan-Meier survival curves were also generated. Results: The median follow-up time for all surviving patients was 5.8 years (range, 9-146 months). The mean and the median minimum tumor doses were 7300 cGy. The 5-year overall survival rate was 71%, and the 5-year progression-free survival rate was 77%. The 5-year overall survival rates by stage were carcinoma in situ with microinvasion and stage I, 92%; stage II, 82%; and stages III and IVA, 20% (P = 0.0005). The 5-year progression-free survival rates by stage were carcinoma in situ and stage I, 92%; stage II, 88%; and stages III and IVA, 30% (P = 0.00049). Of the factors analyzed, only stage predicted for a statistically significant increased risk for recurrence (P = 2.23E-0.05). Conclusions: Early-stage vaginal cancer can be successfully managed with radiation therapy with excellent rates of local control and survival. Patients with stages III and IV disease have a very poor outcome, and more aggressive therapies need to be investigated. Given the limited number of patients treated with chemotherapy and radiation, no definitive conclusions can be made regarding the impact of combined therapy in the management of this disease.

KW - Brachytherapy

KW - Chemotherapy

KW - Radiotherapy

KW - Vaginal cancer

UR - http://www.scopus.com/inward/record.url?scp=67651055468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651055468&partnerID=8YFLogxK

U2 - 10.1111/IGC.0b013e3181a12e1d

DO - 10.1111/IGC.0b013e3181a12e1d

M3 - Article

C2 - 19509572

AN - SCOPUS:67651055468

VL - 19

SP - 686

EP - 693

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 4

ER -